New medicine for orphan and Rare diseases has the capability to undoubtedly impact the lives of patients, where historically there were few or no treatments have been provided to control the sickness. The Orphan Drug Act (ODA) established in 1983 compelled producers to expand scale to treat uncommon/orphan diseases, and the orphan drug panorama has advanced drastically. Approvals for orphan drugs has doubled in the past decade, and there are over 500 applicants in the pipeline for orphan diseases.
MarketsandMarkets Digital Event on Orphan Drugs and Rare Diseases scheduled to be held on 9th -10th July 2020 will provide valuable and necessary platform for uplifting knowledge at the forefront of drug analysis. Over the course of the conference, internationally-renowned speakers can describe how their analysis journeys have developed the response towards up to date challenges. The attending specialists and trade partners will offer an incredible networking expertise.
This conference will gather scientists, researchers, entrepreneurs, academicians, medical officers, CEO’s, CSO’s and technologists from everywhere around the globe to discuss on the newest scientific advances within the field of rare diseases & orphan drugs that facilitate to form current and future challenges in drug analysis.
Senior Vice President, Center for Rare Diseases , PRA Health Sciences
Director, Global Medical Affairs, Early Access , Alnylam Pharmaceuticals
Founder & CEO , rareLife solutions
Global Medical Lead SHP 647 , Shire Pharmaceuticals
Regional Head of Rare Ocular Disease, Novartis
Key Account Manager, en Recordati Rare Diseases
Senior Advisor to the Director NCATS, , NIH
Managing Director of Business Development, Tanner Pharma Group
Chief Operating Officer, HRA Pharma Rare Diseases
PhD- Senior Vice President, Vector Delivery and Optimization, Axovant Sciences
Executive Member of the research and ethics committee, Hospital de Clínicas de Porto Alegre (HCPA)
Director, Global Business Development , Clinigen Group